Búsqueda Imágenes Maps Play YouTube Noticias Gmail Drive Más »
Iniciar sesión
Usuarios de lectores de pantalla: deben hacer clic en este enlace para utilizar el modo de accesibilidad. Este modo tiene las mismas funciones esenciales pero funciona mejor con el lector.

Patentes

  1. Búsqueda avanzada de patentes
Número de publicaciónWO2001002031 A3
Tipo de publicaciónSolicitud
Número de solicitudPCT/US2000/017606
Fecha de publicación6 Dic 2001
Fecha de presentación27 Jun 2000
Fecha de prioridad1 Jul 1999
También publicado comoWO2001002031A2
Número de publicaciónPCT/2000/17606, PCT/US/0/017606, PCT/US/0/17606, PCT/US/2000/017606, PCT/US/2000/17606, PCT/US0/017606, PCT/US0/17606, PCT/US0017606, PCT/US017606, PCT/US2000/017606, PCT/US2000/17606, PCT/US2000017606, PCT/US200017606, WO 0102031 A3, WO 0102031A3, WO 2001/002031 A3, WO 2001002031 A3, WO 2001002031A3, WO-A3-0102031, WO-A3-2001002031, WO0102031 A3, WO0102031A3, WO2001/002031A3, WO2001002031 A3, WO2001002031A3
InventoresJean-Marie Girardot, Marie-Nadia Girardot, Agneta Simionescu, Dan Simionescu
SolicitanteBiomedical Design Inc
Exportar citaBiBTeX, EndNote, RefMan
Enlaces externos:  Patentscope, Espacenet
Targeted anticalcification treatment
WO 2001002031 A3
Resumen
Methods for providing biomaterials with increased resistance to calcification by treating with cell-targeted agents and/or with matrix-targeted agents. Cell-targeted agents are used which block calcium channels or which prevent oxidative damage to cells and/or inhibit enzymes. Other treatments of biomaterials may remove cell-derived calcium-binding components or target extracellular matrices, as by cleaving proteins with cyanogen bromide or reducing disulfide bonds to produce sulfhydryl groups which are thereafter alkylated. Combinations of the foregoing different treatments are also effective in increasing the calcification resistance of cardiovascular tissues that were previously subjected to chemical fixing and/or other anticalcification treatments.
Citas de patentes
Patente citada Fecha de presentación Fecha de publicación Solicitante Título
WO1996013227A1 *20 Oct 19959 May 1996University Of MichiganCalcification-resistant bioprosthetic tissue and methods of making same
EP0564786A2 *12 Feb 199313 Oct 1993Lifecell CorporationMethod for processing and preserving collagen-based tissues for transplantation
US4753652 *10 Dic 198628 Jun 1988Children's Medical Center CorporationBiomaterial implants which resist calcification
US5558875 *6 Jun 199424 Sep 1996Wang; SuMethod of preparing collagenous tissue
US5843182 *27 Ene 19971 Dic 1998Cryolife, Inc.Treated tissue for implantation and methods of preparation
Otras citas
Referencia
1 *HENRY P D: "ANTI-ATHEROSCLEROTIC EFFECTS OF CALCIUM ANTAGONISTS: A BRIEF REVIEW", CLINICAL AND INVESTIGATIVE MEDICINE, vol. 10, no. 6, 1 November 1987 (1987-11-01), pages 601 - 605, XP000604021
Citada por
Patente citante Fecha de presentación Fecha de publicación Solicitante Título
US890029415 Abr 20142 Dic 2014Colibri Heart Valve LlcMethod of controlled release of a percutaneous replacement heart valve
US911973828 Jun 20111 Sep 2015Colibri Heart Valve LlcMethod and apparatus for the endoluminal delivery of intravascular devices
US912573915 Abr 20148 Sep 2015Colibri Heart Valve LlcPercutaneous replacement heart valve and a delivery and implantation system
US91862486 Feb 201217 Nov 2015Colibri Heart Valve LlcPercutaneously implantable replacement heart valve device and method of making same
US955489830 Sep 201431 Ene 2017Colibri Heart Valve LlcPercutaneous prosthetic heart valve
Clasificaciones
Clasificación internacionalA61L27/50
Clasificación cooperativaA61L2400/02, A61L27/50
Clasificación europeaA61L27/50
Eventos legales
FechaCódigoEventoDescripción
11 Ene 2001ALDesignated countries for regional patents
Kind code of ref document: A2
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
11 Ene 2001AKDesignated states
Kind code of ref document: A2
Designated state(s): AU CA JP
7 Mar 2001121Ep: the epo has been informed by wipo that ep was designated in this application
19 Abr 2001DFPERequest for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
6 Dic 2001AKDesignated states
Kind code of ref document: A3
Designated state(s): AU CA JP
6 Dic 2001ALDesignated countries for regional patents
Kind code of ref document: A3
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
4 Sep 2002122Ep: pct application non-entry in european phase
31 Mar 2004NENPNon-entry into the national phase in:
Ref country code: JP